Shots:
- The EC has approved Elahere to treat FRα+, Pt-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer after 1-3 prior treatments, valid across whole EU plus Iceland, Liechtenstein, Norway & Northern Ireland
- Approval was based on P-III (MIRASOL) trial assessing Elahere vs investigator’s choice of CT (weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan) in patients (n=453) to treat FRα+, Pt-resistant, high-grade serous ovarian cancer
- Results showed reduction in progression or death risk by 35% & reduction in death risk by 33%. Common AEs included blurred vision, nausea & fatigue, with pneumonitis as the most serious one. Data was published in the NEJM
Ref: Abbvie | Image: Abbvie| Press Release
Related News:- InflaRx’s Gohibic (Vilobelimab) Gains the CHMP’s Positive Opinion for the Treatment of ARDS
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
